FindTrial
Sign In

Using Blood Tests to Diagnose a Serious Inflammatory Condition Linked to Cancer and its effect on longevity of patient

Epidemiology, Clinical features and outcome predictors of Hemophagocytic Lymphohistiocytosis in the critically ill cancer patients: A retrospective Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/10/075684
Enrollment
100
Registered
2024-10-23
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D80-D89- Certain disorders involving the immune mechanism

Interventions

Intervention1: Nil: NA Control Intervention1: Nil: NA

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients admitted in ICU with suspicion of mal-associated HLH in whom sIL-2 R was measured

Exclusion criteria

Exclusion criteria: Patients with incomplete medical records

Design outcomes

Primary

MeasureTime frame
Epidemiology, clinical characteristics and outcomes of patients with malignancy-associated HLHTimepoint: within last 30 days of occurrence of HLH—

Secondary

MeasureTime frame
sensitivity of sIL-2R in diagnosing malignancy-associated HLHTimepoint: within last 30 days of occurrence of HLH—

Countries

India

Contacts

Public ContactDr Keyur Shah

Tata Memorial Hospital

kaivalyaak@yahoo.co.in9869077526

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026